CA2323422A1 - Chemical process for the production of sulphinyl derivatives by oxidation of the corresponding co-derivatives with perborates - Google Patents
Chemical process for the production of sulphinyl derivatives by oxidation of the corresponding co-derivatives with perborates Download PDFInfo
- Publication number
- CA2323422A1 CA2323422A1 CA002323422A CA2323422A CA2323422A1 CA 2323422 A1 CA2323422 A1 CA 2323422A1 CA 002323422 A CA002323422 A CA 002323422A CA 2323422 A CA2323422 A CA 2323422A CA 2323422 A1 CA2323422 A1 CA 2323422A1
- Authority
- CA
- Canada
- Prior art keywords
- process according
- compound
- och3
- formula
- range
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000007254 oxidation reaction Methods 0.000 title claims description 8
- -1 sulphinyl Chemical class 0.000 title description 7
- 230000003647 oxidation Effects 0.000 title description 5
- 238000001311 chemical methods and process Methods 0.000 title description 2
- 238000004519 manufacturing process Methods 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 53
- 150000003839 salts Chemical class 0.000 claims abstract description 32
- 239000003085 diluting agent Substances 0.000 claims abstract description 29
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract description 28
- 150000001875 compounds Chemical class 0.000 claims abstract description 26
- 239000007788 liquid Substances 0.000 claims abstract description 26
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims abstract description 7
- 238000009835 boiling Methods 0.000 claims abstract description 6
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 48
- 239000000203 mixture Substances 0.000 claims description 48
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 27
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 24
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- 238000000746 purification Methods 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 11
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 11
- 229960001922 sodium perborate Drugs 0.000 claims description 9
- YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical group [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 7
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 5
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 claims description 4
- 150000002009 diols Chemical class 0.000 claims description 4
- 238000002955 isolation Methods 0.000 claims description 4
- 229960000381 omeprazole Drugs 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical group COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 229930195733 hydrocarbon Natural products 0.000 claims description 2
- 150000002430 hydrocarbons Chemical group 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 239000004215 Carbon black (E152) Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 239000012418 sodium perborate tetrahydrate Substances 0.000 description 12
- IBDSNZLUHYKHQP-UHFFFAOYSA-N sodium;3-oxidodioxaborirane;tetrahydrate Chemical compound O.O.O.O.[Na+].[O-]B1OO1 IBDSNZLUHYKHQP-UHFFFAOYSA-N 0.000 description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- 239000002585 base Substances 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 238000003756 stirring Methods 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- CXBDYQVECUFKRK-UHFFFAOYSA-N 1-methoxybutane Chemical compound CCCCOC CXBDYQVECUFKRK-UHFFFAOYSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- LCJDHJOUOJSJGS-UHFFFAOYSA-N 2-(chloromethyl)-4-methoxy-3,5-dimethylpyridin-1-ium;chloride Chemical compound Cl.COC1=C(C)C=NC(CCl)=C1C LCJDHJOUOJSJGS-UHFFFAOYSA-N 0.000 description 3
- PLITYYGQMDTHMM-UHFFFAOYSA-N 2-(pyridin-2-ylmethylsulfanyl)-1h-benzimidazole Chemical class N=1C2=CC=CC=C2NC=1SCC1=CC=CC=N1 PLITYYGQMDTHMM-UHFFFAOYSA-N 0.000 description 3
- KOFBRZWVWJCLGM-UHFFFAOYSA-N 5-methoxy-1,3-dihydrobenzimidazole-2-thione Chemical compound COC1=CC=C2NC(S)=NC2=C1 KOFBRZWVWJCLGM-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- CCHLMSUZHFPSFC-UHFFFAOYSA-N 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfanyl]-1h-benzimidazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CSC1=NC2=CC=CC=C2N1 CCHLMSUZHFPSFC-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 229960003174 lansoprazole Drugs 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 229960005019 pantoprazole Drugs 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 125000001174 sulfone group Chemical group 0.000 description 2
- BGRMWANKLIXEKN-UHFFFAOYSA-N 1-iodosyl-2-methylbenzene Chemical compound CC1=CC=CC=C1I=O BGRMWANKLIXEKN-UHFFFAOYSA-N 0.000 description 1
- HBDKFZNDMVLSHM-UHFFFAOYSA-N 2-(pyridin-2-ylmethylsulfinyl)-1h-benzimidazole Chemical class N=1C2=CC=CC=C2NC=1S(=O)CC1=CC=CC=N1 HBDKFZNDMVLSHM-UHFFFAOYSA-N 0.000 description 1
- XSVSPKKXQGNHMD-UHFFFAOYSA-N 5-bromo-3-methyl-1,2-thiazole Chemical group CC=1C=C(Br)SN=1 XSVSPKKXQGNHMD-UHFFFAOYSA-N 0.000 description 1
- UKILEIRWOYBGEJ-UHFFFAOYSA-N 6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfanyl]-1h-benzimidazole Chemical compound COC1=CC=NC(CSC=2NC3=CC(OC(F)F)=CC=C3N=2)=C1OC UKILEIRWOYBGEJ-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- XHCLAFWTIXFWPH-UHFFFAOYSA-N [O-2].[O-2].[O-2].[O-2].[O-2].[V+5].[V+5] Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[V+5].[V+5] XHCLAFWTIXFWPH-UHFFFAOYSA-N 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- JYJVVHFRSFVEJM-UHFFFAOYSA-N iodosobenzene Chemical compound O=IC1=CC=CC=C1 JYJVVHFRSFVEJM-UHFFFAOYSA-N 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- USSBDBZGEDUBHE-UHFFFAOYSA-L magnesium;2-oxidooxycarbonylbenzoate Chemical compound [Mg+2].[O-]OC(=O)C1=CC=CC=C1C([O-])=O USSBDBZGEDUBHE-UHFFFAOYSA-L 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229910001935 vanadium oxide Inorganic materials 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Abstract
A process for the preparation of a compound of formula (I) in which R1, R2, R3 and R4 represent: a) (R1=CH3; R2=OCH3; R3=CH3; R4=OCH3) or b) (R1=CH3; R2=OCH2CF3; R3=H; R4=H) or c) (R1=OCH3; R2=OCH3; R3=H and R4=OCHF2) respectively and pharmaceutically acceptable salts thereof, comprising reacting a compound of formula (II) in which R1, R2, R3 and R4 represent a) (R1=CH3; R2=OCH3; R3=CH3, R4=OCH3) or b) (R1=CH3; R2=OCH2CF3; R3=H; R4=H) or c) R1=OCH3; R2=OCH3; R3=H and R4=OCHF2) respectively, with a perborate salt in a liquid diluent at a pH in the range of 7.5 to 14 at a temperature in the range of 0 ~C to the boiling point of the liquid diluent employed.
Description
w CHEMICAL PROCESS FOR THE PRODUCTION OF SULPHINYL DERIVATIVES BY OXIDATION OF
THE CORRESPONDING THIO-DERIUATIYES WITH PERBORATES
The present invention describes an improved process for the preparation of substituted 2-(2-pyridylmethyl)sulphinyl-1 H benzimidazoles particularly omeprazole, lansoprazole and pantoprazole by oxidising the corresponding substituted 2-(2-pyridylmethylthio)-1 H benzimidazole.
Several proton-pump inhibitors, which are useful in the treatment of duodenal ulcers, of formula A are known. These include omeprazole (R~=CH3; R2=OCH3;
R3=CH3; R4=OCH3) which is described in EP5129, lansoprazole (R~=CH3;
RZ=OCH2CF3; R3=H; R4=H) which is described in EP174,726 and pantoprazole (R~=OCH3; R2=OCH3; R3=H and R4=OCHF2) which is described in EP166,287.
Rz N ~ R~ / R3 /~S NJ A
R ~N
Many methods for preparing such compounds by the oxidation of the corresponding 2-(2-pyridylmethylthio)-1 H benzimidazole have been described.
Examples of the oxidising agents used are 3-chloroperoxybenzoic acid (V11091118895, EP533752, US5,386,032, ES43816 and EP484265), magnesium monoperoxyphthalate (EP533264 and US5,391,752), ammonium molybdate (EP484,265), iodosobenzene (ES539793), methyliodosobenzene (ES540147), sodium periodate (ES550070) and vanadium oxide (EP302720).
However, there remains a need for a cheap and efficient process for oxidising 2-(2-pyridylmethylthio)-1 H benzimidazoles which is reliable, produces waste streams which are easily disposed of without causing harm to the environment and produces a stable final product.
The present invention provides a process for the preparation of a compound of formula I
Rz O R~ / Rs J I
\ I /~S N
R N
in which R~, R2, R3 and R4 represent a) (R~=CH3; R2=OCH3; R3=CH3; R4=OCH3) or b) (R~=CH3; R2=OCH2CF3; R3=H; R4=H) or c) (R~=OCH3; R2=OCH3; R3=H and R4=OCHFz) respectively and pharmaceutically acceptable salts thereof comprising reacting a compound of formula II
N R~ / R3 / I
\ ( ,~S N J I I
R ~N
in which R~, R2, R3 and R4 represent a) (R~=CH3; R2=OCH3; R3=CH3; R4=OCH3) or b) (R~=CH3; RZ=OCH2CF3; R3=H; R4=H) or c) (R~=OCH3; RZ=OCH3; R3=H and R4=OCHF2) respectively with a perborate salt in a liquid diluent at a pH in the range of 7.5 to 14 at a temperature in the range of 0°C to the boiling point of the liquid diluent employed.
Suitably the perborate salt is a metallic perborate salt or an ammonium perborate salt. The perborate salt may be anhydrous or hydrated. Preferably the perborate salt is potassium or sodium perborate. More preferably the perborate salt is sodium perborate. Most preferably the perborate salt is sodium perborate monohydrate or sodium perborate tetrahydrate.
Suitably the amount of perborate salt employed in the process is in the range of 0.8 to 3 moles per mole of the compound of formula II employed in the process.
_ WO 99/47514 PCT/EP99/01574 Preferably the amount of perborate employed is in the range 0.95-2.0 moles per mole of the compound of formula II employed in the process. More preferably the amount of perborate employed is in the range 1.0-1.9 moles per mole of the compound of formula II employed in the process for example 1.1-1.5 moles per mole of the compound of formula II. Most preferably the amount of perborate employed is in the range 1.4-1.8 moles per mole of the compound of formula 11 employed in the process.
The purpose of the liquid diluent is to allow contact between the compound of formula II and the perborate salt at the required temperature. Any liquid diluent, which is inert to the reactants, in which this purpose is achieved may be used.
Preferably the liquid diluent is selected from water, a C» alcohol, toluene, tetrahydrofuran, acetone, a CZ_s diol, a C~ triol, ethyl acetate or mixtures thereof.
More preferably the liquid diluent is a water/alcohol mixture, for example a water/methanol or a water/ethanol mixture. Most preferably the diluent is a water/methanol mixture optionally containing toluene.
Preferably the process is carried out at a pH in the range of 8.5 to 12. More preferably 10 to 12. Most preferably the process is carried out at a pH in the range of 10 to 11.
Suitably the pH of the process is controlled by the addition of a base for example an alkali metal hydroxide an alkali metal carbonate, an alkali metal bicarbonate or an amine e.g. ammonia or an organic amine or mixtures thereof.
Preferably the base is sodium hydroxide.
It will be appreciated by those skilled in the art that when the reaction is carried out at high pH a salt of the desired product may be obtained. Lowering the pH of the reaction mixture, for example by addition of an acid or preferably of a less basic base, allows the isolation of the compound of formula ! as the free heterocycle.
Preferably the process is carried out at a temperature in the range of 0 to 150°C and more preferably in the range of 15 to 115°C. Most preferably the process is carried out at a temperature in the range of 40 to 55°C, particularly at a temperature in the range of 45 to 50°C.
The process of the present invention has severa! advantages over previously described oxidation processes. The reagents employed are cheap, non-hazardous and environmentally friendly, for example sodium perborate is used in domestic washing powder, in mouth washes and in cleaning fluids for contact lenses.
Sodium perborate has exceptional storage stability and is not shock sensitive. The process gives good yields reproducibly and provides a product of high purity which is chemically more stable than the products of other oxidation processes especially those carried out in acidic conditions. In addition environmentally friendly liquid diluents may be used.
The process of the present invention has two further advantages over the prior art processes. Firstly, this process step may be combined with the previous process step and thus avoid isolation of the compound of formula 1i. This leads to cost reduction in the process through improved processing times. Secondly, in comparative experiments sodium perborate appears to give fewer impurities arising from over-oxidation, for example formation of a sulphone, or an N oxide, or a sulphone N oxide, than previously known oxidants, for example 3-chloroperoxy-benzoic acid.
The desired product can be isolated from the reaction mixture and purified by conventional means e.g. extraction and recrystallisation or filtration followed optionally by recrystallisation.
In a preferred process of the present invention a compound of formula Ila is reacted with sodium perborate in a mixture of water and methanol at a pH in the range of 8.5 to 10 at a temperature in the range of 15 -115°C to give a compound of formula la (omeprazole).
In a more preferred process of the present invention the compound of formula II is prepared by reacting a compound of formula III
WO 99/47514 PCT/EP99/Oi574 a I /~SH
R ~ N
or a salt thereof in which R4 is as previously defined with a compound of formula IV
Rz R~ / Rs cl NJ
IV
THE CORRESPONDING THIO-DERIUATIYES WITH PERBORATES
The present invention describes an improved process for the preparation of substituted 2-(2-pyridylmethyl)sulphinyl-1 H benzimidazoles particularly omeprazole, lansoprazole and pantoprazole by oxidising the corresponding substituted 2-(2-pyridylmethylthio)-1 H benzimidazole.
Several proton-pump inhibitors, which are useful in the treatment of duodenal ulcers, of formula A are known. These include omeprazole (R~=CH3; R2=OCH3;
R3=CH3; R4=OCH3) which is described in EP5129, lansoprazole (R~=CH3;
RZ=OCH2CF3; R3=H; R4=H) which is described in EP174,726 and pantoprazole (R~=OCH3; R2=OCH3; R3=H and R4=OCHF2) which is described in EP166,287.
Rz N ~ R~ / R3 /~S NJ A
R ~N
Many methods for preparing such compounds by the oxidation of the corresponding 2-(2-pyridylmethylthio)-1 H benzimidazole have been described.
Examples of the oxidising agents used are 3-chloroperoxybenzoic acid (V11091118895, EP533752, US5,386,032, ES43816 and EP484265), magnesium monoperoxyphthalate (EP533264 and US5,391,752), ammonium molybdate (EP484,265), iodosobenzene (ES539793), methyliodosobenzene (ES540147), sodium periodate (ES550070) and vanadium oxide (EP302720).
However, there remains a need for a cheap and efficient process for oxidising 2-(2-pyridylmethylthio)-1 H benzimidazoles which is reliable, produces waste streams which are easily disposed of without causing harm to the environment and produces a stable final product.
The present invention provides a process for the preparation of a compound of formula I
Rz O R~ / Rs J I
\ I /~S N
R N
in which R~, R2, R3 and R4 represent a) (R~=CH3; R2=OCH3; R3=CH3; R4=OCH3) or b) (R~=CH3; R2=OCH2CF3; R3=H; R4=H) or c) (R~=OCH3; R2=OCH3; R3=H and R4=OCHFz) respectively and pharmaceutically acceptable salts thereof comprising reacting a compound of formula II
N R~ / R3 / I
\ ( ,~S N J I I
R ~N
in which R~, R2, R3 and R4 represent a) (R~=CH3; R2=OCH3; R3=CH3; R4=OCH3) or b) (R~=CH3; RZ=OCH2CF3; R3=H; R4=H) or c) (R~=OCH3; RZ=OCH3; R3=H and R4=OCHF2) respectively with a perborate salt in a liquid diluent at a pH in the range of 7.5 to 14 at a temperature in the range of 0°C to the boiling point of the liquid diluent employed.
Suitably the perborate salt is a metallic perborate salt or an ammonium perborate salt. The perborate salt may be anhydrous or hydrated. Preferably the perborate salt is potassium or sodium perborate. More preferably the perborate salt is sodium perborate. Most preferably the perborate salt is sodium perborate monohydrate or sodium perborate tetrahydrate.
Suitably the amount of perborate salt employed in the process is in the range of 0.8 to 3 moles per mole of the compound of formula II employed in the process.
_ WO 99/47514 PCT/EP99/01574 Preferably the amount of perborate employed is in the range 0.95-2.0 moles per mole of the compound of formula II employed in the process. More preferably the amount of perborate employed is in the range 1.0-1.9 moles per mole of the compound of formula II employed in the process for example 1.1-1.5 moles per mole of the compound of formula II. Most preferably the amount of perborate employed is in the range 1.4-1.8 moles per mole of the compound of formula 11 employed in the process.
The purpose of the liquid diluent is to allow contact between the compound of formula II and the perborate salt at the required temperature. Any liquid diluent, which is inert to the reactants, in which this purpose is achieved may be used.
Preferably the liquid diluent is selected from water, a C» alcohol, toluene, tetrahydrofuran, acetone, a CZ_s diol, a C~ triol, ethyl acetate or mixtures thereof.
More preferably the liquid diluent is a water/alcohol mixture, for example a water/methanol or a water/ethanol mixture. Most preferably the diluent is a water/methanol mixture optionally containing toluene.
Preferably the process is carried out at a pH in the range of 8.5 to 12. More preferably 10 to 12. Most preferably the process is carried out at a pH in the range of 10 to 11.
Suitably the pH of the process is controlled by the addition of a base for example an alkali metal hydroxide an alkali metal carbonate, an alkali metal bicarbonate or an amine e.g. ammonia or an organic amine or mixtures thereof.
Preferably the base is sodium hydroxide.
It will be appreciated by those skilled in the art that when the reaction is carried out at high pH a salt of the desired product may be obtained. Lowering the pH of the reaction mixture, for example by addition of an acid or preferably of a less basic base, allows the isolation of the compound of formula ! as the free heterocycle.
Preferably the process is carried out at a temperature in the range of 0 to 150°C and more preferably in the range of 15 to 115°C. Most preferably the process is carried out at a temperature in the range of 40 to 55°C, particularly at a temperature in the range of 45 to 50°C.
The process of the present invention has severa! advantages over previously described oxidation processes. The reagents employed are cheap, non-hazardous and environmentally friendly, for example sodium perborate is used in domestic washing powder, in mouth washes and in cleaning fluids for contact lenses.
Sodium perborate has exceptional storage stability and is not shock sensitive. The process gives good yields reproducibly and provides a product of high purity which is chemically more stable than the products of other oxidation processes especially those carried out in acidic conditions. In addition environmentally friendly liquid diluents may be used.
The process of the present invention has two further advantages over the prior art processes. Firstly, this process step may be combined with the previous process step and thus avoid isolation of the compound of formula 1i. This leads to cost reduction in the process through improved processing times. Secondly, in comparative experiments sodium perborate appears to give fewer impurities arising from over-oxidation, for example formation of a sulphone, or an N oxide, or a sulphone N oxide, than previously known oxidants, for example 3-chloroperoxy-benzoic acid.
The desired product can be isolated from the reaction mixture and purified by conventional means e.g. extraction and recrystallisation or filtration followed optionally by recrystallisation.
In a preferred process of the present invention a compound of formula Ila is reacted with sodium perborate in a mixture of water and methanol at a pH in the range of 8.5 to 10 at a temperature in the range of 15 -115°C to give a compound of formula la (omeprazole).
In a more preferred process of the present invention the compound of formula II is prepared by reacting a compound of formula III
WO 99/47514 PCT/EP99/Oi574 a I /~SH
R ~ N
or a salt thereof in which R4 is as previously defined with a compound of formula IV
Rz R~ / Rs cl NJ
IV
5 or a salt thereof in which R~, R2, and R3 are as previously defined, in a second liquid diluent at a pH in the range of 7.5 to 14 at a temperature in the range of 0°C to the boiling point of the second liquid diluent employed and is then reacted with a perborate salt without isolation.
The purpose of the second liquid diluent is to allow contact between the compound of formula III and the compound of formula IV at the required temperature.
Any liquid diluent, which is inert to the reactants, in which this purpose is achieved may be used. Preferably the reaction of III and IV is carried out at a temperature in the range of 10-100°C, preferably at a temperature in the range of 20-80°C and more preferably at a temperature in the range of 40-60°C.
Preferably the second liquid diluent is selected from water, a C~~ alcohol, toluene, tetrahydrofuran, acetone, a CZ~ diol, a C3.s triol, ethyl acetate or mixtures thereof. More preferably the second liquid diluent is a water/alcohoi mixture, for example a wateNmethanol or a waterlethanol mixture. Most preferably the diluent is a water/methanol mixture optionally containing toluene. Especially preferably the second liquid diluent is the same as the first liquid diluent. This avoids further processing for example diluent exchange.
The purpose of the second liquid diluent is to allow contact between the compound of formula III and the compound of formula IV at the required temperature.
Any liquid diluent, which is inert to the reactants, in which this purpose is achieved may be used. Preferably the reaction of III and IV is carried out at a temperature in the range of 10-100°C, preferably at a temperature in the range of 20-80°C and more preferably at a temperature in the range of 40-60°C.
Preferably the second liquid diluent is selected from water, a C~~ alcohol, toluene, tetrahydrofuran, acetone, a CZ~ diol, a C3.s triol, ethyl acetate or mixtures thereof. More preferably the second liquid diluent is a water/alcohoi mixture, for example a wateNmethanol or a waterlethanol mixture. Most preferably the diluent is a water/methanol mixture optionally containing toluene. Especially preferably the second liquid diluent is the same as the first liquid diluent. This avoids further processing for example diluent exchange.
In a preferred embodiment the compound of formula III is present as the free thiol, initially, and the process is carried out in the presence of a base.
Preferably the base is an alkali metal hydroxide for example sodium hydroxide or potassium hydroxide. More preferably the base is sodium hydroxide.
In a preferred embodiment the compound of formula IV is present as a salt and sufficient base is used in the process to neutralise the salt of the compound of formula 1V and to form a salt of the compound of formula III. Preferably the salt of the compound of formula IV is the hydrochloride salt, the hydrobromide salt, the acetate salt, the nitrate salt or a salt of sulphuric acid or the salt of a phosphoric acid. Most preferably the salt is the hydrochloride salt.
Preferably the amount of base employed is in the range of 2.0 to 5.0 moles per mole of the compound of formula III. More preferably the amount of base employed is in the range of 3 to 4 moles per mole of the compound of formula II(.
1n a preferred embodiment of the process a purification solvent is added at the end of the oxidation reaction. The purification solvent has been found to remove certain impurities from the crude reaction product by dissolving these impurities so that on filtration the product obtained requires fewer recrystallisations than would otherwise be necessary. This provides time and energy and therefore cost savings in the process. The purification solvent also aids the filtration process by changing the physical nature of the product so that it can be more readily filtered.
Preferably the purification solvent is immiscible with the liquid diluent.
Preferred purification solvents are hydrocarbons, including aliphatic and aromatic hydrocarbons, and ethers, particularly di(C~_salkyl) ethers in which the alkyl groups are the same or different, and esters, for example ethyl acetate and mixtures thereof. More preferably the purification solvent is tent butyl methyl ether, diisopropyl ether, hexane , heptane or toluene and mixtures thereof. Most preferably the purification solvent is tent butyl methyl ether, diisopropyl ether or hexane and mixtures thereof. Especially preferably the purification solvent is tern butyl methyl ether or diisopropyl ether.
_ WO 99/47514 PCT/EP99/01574 The invention is illustrated by the following Examples which are given by way of example only. The final product of each of these Examples was characterised by one or more of the following procedures: high pertormance liquid chromatography;
elemental analysis, nuclear magnetic resonance spectroscopy, infrared spectroscopy and high resolution mass spectroscopy. The compounds of formula II, III and IV
used in the Examples were either commercially available or were prepared by the methods given in EP5129, EP174,726 or EP166,287 which are incorporated herein by reference.
Example 1 A solution of sodium hydroxide pellets (0.32 g), sodium perborate tetrahydrate (1.43 g) and water (35 ml) was prepared by stirring and heating the mixed components until a solution was obtained, and was then added dropwise with stirring over 2.5 hours to a solution of 5-methoxy-2-{((4-methoxy-3,5-dimethyl-pyridin-2-y!)methyl]thio}-1 H benzimidazole (2.0 g) in methanol (20 ml) and toluene (2 ml) which was boiling under reflux. The methanol was removed under reduced pressure and the residue was cooled to 50°C and then added to saturated sodium bicarbonate solution (20 ml). The mixture was extracted with dichloromethane (2 x 10 ml), the combined extracts were dried, filtered and evaporated to give 5-methoxy-2-{((4-methoxy-3, 5-dimethyl-pyridin-2-yl)methyl]sulphinyl}-1 H-benzimidazole (1.60 g). Yield 86.5%.
Example 2 A solution was prepared by dissolving sodium hydroxide pellets (17.7 g) and sodium perborate tetrahydrate (68.3 g) in water (1085 ml) with stirring and heating and this solution was then added dropwise to a solution of 5-methoxy-2-{[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methylJthio}-1H-benzimidazole (83.4 g) in methanol (834 ml) whilst the mixture was boiled under reflux. The methanol was removed under reduced pressure and the residue was cooled to 50°C and then added to saturated sodium bicarbonate solution (830 ml). The mixture was cooled to 30°C and extracted with dichloromethane (2 x 400 ml). The combined dichloromethane extracts were dried over magnesium sulphate, filtered and WO 99/47514 PC1'/EP99/01574 evaporated to give give 5-methoxy-2-{[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methyl]sulphinyl}-1H benzimidazole (74.0 g, 84.fi% yield). This material was stirred in ethyl acetate {222 ml) for 1 hour then filtered. The residue was washed with ethyl acetate (2 x 25 ml) and dried to give a product which was 96.7% pure by HPLC.
Example 3 A solution of sodium hydroxide (1.0 g) and sodium perborate tetrahydrate (3.8 g) in water (65.0 ml) was prepared by heating and stirring. This solution was then added dropwise to a solution of 2-[3-methyl-4-(2,2,2-trifluoroethoxy)pyrid-2-ylmethylthio]-1 H-benzimidazole (5.0 g) in methanol (50.0 ml) which was being boiled over 2 hours at reflux with stirring. The mixture was stirred and boiled for a further 15 minutes, then the methanol and water were removed under reduced pressure to give a residue which was cooled to 50°C and added to saturated sodium bicarbonate solution (50.0 ml). This mixture was cooled to 30°C and then extracted with dichloromethane (2 x 25 ml). The combined extracts were dried, filtered and evaporated to give 2-[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinylmethylsulphinyl]-1 H-benzimidazole (4.8 g, 92.3% yield). The purity of this material was 90.3%
by HPLC. This solid was stirred with ethyl acetate (14.4 ml) for 1 hour and then the solid collected by filtration, washed with ethyl acetate and dried to give material which was 91.4% pure by HPLC.
Example 4 A solution of sodium hydroxide (9.8 g) and sodium perborate tetrahydrate (37.3 g) in water (638.3 g) was prepared by heating and stirring. This solution was then added dropwise over 2.5 hours to a solution of 2-[3-methyl-4-(2,2,2-trifluoroethoxy)pyrid-2-ylmethylthio]-1 H-benzimidazole (49.1 g) in methanol (491.0 ml) which was being boiled at reflux with stirring. The mixture was stirred and boiled for a further 15 minutes, then the methanol and water were removed under reduced pressure to give a residue which was cooled to 50°C and added to saturated sodium bicarbonate solution (491 ml). This mixture was cooled to 30°C
and then extracted with dichloromethane (2 x 245.5 ml). The combined extracts were dried, filtered and evaporated to give 2-[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinylmethylsulphinylj-1H benzimidazole in quantitative yield.
Example 5 In a similar manner to Example 1, 5-(difluoromethoxy)-2-[(3,4-dimethoxy-2-pyridinyl)methylthio]-1 H benzimidazole is reacted with sodium perborate to give 5-(difluoromethoxy)-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphinylj-1H
benzimidazole.
Example 6 A mixture of 5-methoxy-2-mercapto-1 H-benzimidazole (198.8 g), methanol (380 ml) and water (760 ml) was stirred while sodium hydroxide solution (215 ml, 46-48% w/w) was added over 5 minutes. The mixture was stirred at 45-50°C and a solution of 2-chloromethyl-4-methoxy-3,5-dimethylpyridine hydrochloride (245 g) in water (1136 ml) was added over 1 hour. The mixture was stirred at 45-50°C for 2 hours and then sodium perborate tetrahydrate (202.4 g) was added. The mixture was stirred at 45-50°C for 18 hours. Further sodium perborate tetrahydrate (16 g) was added and the mixture was stirred for a further 4 hours. The mixture was cooled to 30-35°C and sodium hydrogen carbonate (221.9 g) was added followed by water (763.4 ml) and tert-butyl methyl ether (763.4 ml). The mixture was stirred vigorously for 2 hours then filtered to give a product which was washed with ter# butyl methyl ether (500 ml) and then dried under vacuum at 45-50°C for 21 hours to give 5-methoxy-2-{[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methyljsulphinyl}-1 H-benzimidazole (293.4 g, 77% yield, purity by HPLC 98.3%).
Example 7 A mixture of 5-methoxy-2-mercapto-1 H-benzimidazole (4.3 g), methanol (8.4 ml) and water (16.7 ml) was stin-ed while sodium hydroxide solution (4.7 ml, 46-48% wlw) was added over 5 minutes. The mixture was stirred at 45-50°C and a solution of 2-chloromethyl-4-methoxy-3,5-dimethylpyridine hydrochloride (5.3 g) in water (25 ml) was added over 35 minutes at 45-50°C. The mixture was stirred at 45-50°C for 1.75 hours and then sodium perborate tetrahydrate (4.5 g) was added.
The mixture was stirred at 45-50°C for 20 hours. Further sodium perborate tetrahydrate (0.35 g) was added and the mixture was stirred at 45-50°C
for a further 3 hours. A final batch of sodium perborate tetrahydrate (0.35 g) was added and the mixture stirred for a further 2 hours at 45-50°C. The mixture was cooled to 35°C and 5 sodium hydrogen carbonate (4.9 g) was added followed by water (16.7 ml) and diisopropyl ether (16.2 ml). The mixture was stirred rapidly at 20-25°C
for 1.5 hours.
The mixture was filtered to give a product which was washed with water and dried under vacuum at 45-50°C to give 5-methoxy-2-{[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methyl]sulphinyl}-1 H benzimidazole (6.5 g, 78.9% yield, purity by HPLC
95.5%).
Example 8 A mixture of 5-methoxy-2-mercapto-1 H-benzimidazole (4.3 g), methanol (8.4 ml) and water (16.7 ml) was stirred while sodium hydroxide solution (4.7 ml, 46-48% w/w) was added over 5 minutes. The mixture was stirred at 45-50°C and a solution of 2-chloromethyl-4-methoxy-3,5-dimethylpyridine hydrochloride (5.3 g) in water (25 ml) was added over 35 minutes at 45-50°C. The mixture was stirred at 45-50°C for 1.75 hours and then sodium perborate tetrahydrate (4.5 g) was added.
The mixture was stirred at 45-50°C for 20 hours. Further sodium perborate tetrahydrate (0.35 g) was added and the mixture was stirred at 45-50°C
for a further 3 hours. The mixture was cooled to 35°C and sodium , hydrogen carbonate (4.9 g) was added followed by water (16.7 ml) and hexane (16.7 ml). The mixture was stirred rapidly at 20-25°C for 1.5 hours. The mixture was filtered to give a product which was washed with water and dried under vacuum at 45-50°C to give 5-methoxy-2-~[(4-methoxy-3,5-dimethyl-pyridin-2-yi)methyl]sulphinyl}-1H
benzimidazole (6.6 g, 80.4% yield, purity by HPLC 94.45%).
Preferably the base is an alkali metal hydroxide for example sodium hydroxide or potassium hydroxide. More preferably the base is sodium hydroxide.
In a preferred embodiment the compound of formula IV is present as a salt and sufficient base is used in the process to neutralise the salt of the compound of formula 1V and to form a salt of the compound of formula III. Preferably the salt of the compound of formula IV is the hydrochloride salt, the hydrobromide salt, the acetate salt, the nitrate salt or a salt of sulphuric acid or the salt of a phosphoric acid. Most preferably the salt is the hydrochloride salt.
Preferably the amount of base employed is in the range of 2.0 to 5.0 moles per mole of the compound of formula III. More preferably the amount of base employed is in the range of 3 to 4 moles per mole of the compound of formula II(.
1n a preferred embodiment of the process a purification solvent is added at the end of the oxidation reaction. The purification solvent has been found to remove certain impurities from the crude reaction product by dissolving these impurities so that on filtration the product obtained requires fewer recrystallisations than would otherwise be necessary. This provides time and energy and therefore cost savings in the process. The purification solvent also aids the filtration process by changing the physical nature of the product so that it can be more readily filtered.
Preferably the purification solvent is immiscible with the liquid diluent.
Preferred purification solvents are hydrocarbons, including aliphatic and aromatic hydrocarbons, and ethers, particularly di(C~_salkyl) ethers in which the alkyl groups are the same or different, and esters, for example ethyl acetate and mixtures thereof. More preferably the purification solvent is tent butyl methyl ether, diisopropyl ether, hexane , heptane or toluene and mixtures thereof. Most preferably the purification solvent is tent butyl methyl ether, diisopropyl ether or hexane and mixtures thereof. Especially preferably the purification solvent is tern butyl methyl ether or diisopropyl ether.
_ WO 99/47514 PCT/EP99/01574 The invention is illustrated by the following Examples which are given by way of example only. The final product of each of these Examples was characterised by one or more of the following procedures: high pertormance liquid chromatography;
elemental analysis, nuclear magnetic resonance spectroscopy, infrared spectroscopy and high resolution mass spectroscopy. The compounds of formula II, III and IV
used in the Examples were either commercially available or were prepared by the methods given in EP5129, EP174,726 or EP166,287 which are incorporated herein by reference.
Example 1 A solution of sodium hydroxide pellets (0.32 g), sodium perborate tetrahydrate (1.43 g) and water (35 ml) was prepared by stirring and heating the mixed components until a solution was obtained, and was then added dropwise with stirring over 2.5 hours to a solution of 5-methoxy-2-{((4-methoxy-3,5-dimethyl-pyridin-2-y!)methyl]thio}-1 H benzimidazole (2.0 g) in methanol (20 ml) and toluene (2 ml) which was boiling under reflux. The methanol was removed under reduced pressure and the residue was cooled to 50°C and then added to saturated sodium bicarbonate solution (20 ml). The mixture was extracted with dichloromethane (2 x 10 ml), the combined extracts were dried, filtered and evaporated to give 5-methoxy-2-{((4-methoxy-3, 5-dimethyl-pyridin-2-yl)methyl]sulphinyl}-1 H-benzimidazole (1.60 g). Yield 86.5%.
Example 2 A solution was prepared by dissolving sodium hydroxide pellets (17.7 g) and sodium perborate tetrahydrate (68.3 g) in water (1085 ml) with stirring and heating and this solution was then added dropwise to a solution of 5-methoxy-2-{[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methylJthio}-1H-benzimidazole (83.4 g) in methanol (834 ml) whilst the mixture was boiled under reflux. The methanol was removed under reduced pressure and the residue was cooled to 50°C and then added to saturated sodium bicarbonate solution (830 ml). The mixture was cooled to 30°C and extracted with dichloromethane (2 x 400 ml). The combined dichloromethane extracts were dried over magnesium sulphate, filtered and WO 99/47514 PC1'/EP99/01574 evaporated to give give 5-methoxy-2-{[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methyl]sulphinyl}-1H benzimidazole (74.0 g, 84.fi% yield). This material was stirred in ethyl acetate {222 ml) for 1 hour then filtered. The residue was washed with ethyl acetate (2 x 25 ml) and dried to give a product which was 96.7% pure by HPLC.
Example 3 A solution of sodium hydroxide (1.0 g) and sodium perborate tetrahydrate (3.8 g) in water (65.0 ml) was prepared by heating and stirring. This solution was then added dropwise to a solution of 2-[3-methyl-4-(2,2,2-trifluoroethoxy)pyrid-2-ylmethylthio]-1 H-benzimidazole (5.0 g) in methanol (50.0 ml) which was being boiled over 2 hours at reflux with stirring. The mixture was stirred and boiled for a further 15 minutes, then the methanol and water were removed under reduced pressure to give a residue which was cooled to 50°C and added to saturated sodium bicarbonate solution (50.0 ml). This mixture was cooled to 30°C and then extracted with dichloromethane (2 x 25 ml). The combined extracts were dried, filtered and evaporated to give 2-[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinylmethylsulphinyl]-1 H-benzimidazole (4.8 g, 92.3% yield). The purity of this material was 90.3%
by HPLC. This solid was stirred with ethyl acetate (14.4 ml) for 1 hour and then the solid collected by filtration, washed with ethyl acetate and dried to give material which was 91.4% pure by HPLC.
Example 4 A solution of sodium hydroxide (9.8 g) and sodium perborate tetrahydrate (37.3 g) in water (638.3 g) was prepared by heating and stirring. This solution was then added dropwise over 2.5 hours to a solution of 2-[3-methyl-4-(2,2,2-trifluoroethoxy)pyrid-2-ylmethylthio]-1 H-benzimidazole (49.1 g) in methanol (491.0 ml) which was being boiled at reflux with stirring. The mixture was stirred and boiled for a further 15 minutes, then the methanol and water were removed under reduced pressure to give a residue which was cooled to 50°C and added to saturated sodium bicarbonate solution (491 ml). This mixture was cooled to 30°C
and then extracted with dichloromethane (2 x 245.5 ml). The combined extracts were dried, filtered and evaporated to give 2-[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinylmethylsulphinylj-1H benzimidazole in quantitative yield.
Example 5 In a similar manner to Example 1, 5-(difluoromethoxy)-2-[(3,4-dimethoxy-2-pyridinyl)methylthio]-1 H benzimidazole is reacted with sodium perborate to give 5-(difluoromethoxy)-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphinylj-1H
benzimidazole.
Example 6 A mixture of 5-methoxy-2-mercapto-1 H-benzimidazole (198.8 g), methanol (380 ml) and water (760 ml) was stirred while sodium hydroxide solution (215 ml, 46-48% w/w) was added over 5 minutes. The mixture was stirred at 45-50°C and a solution of 2-chloromethyl-4-methoxy-3,5-dimethylpyridine hydrochloride (245 g) in water (1136 ml) was added over 1 hour. The mixture was stirred at 45-50°C for 2 hours and then sodium perborate tetrahydrate (202.4 g) was added. The mixture was stirred at 45-50°C for 18 hours. Further sodium perborate tetrahydrate (16 g) was added and the mixture was stirred for a further 4 hours. The mixture was cooled to 30-35°C and sodium hydrogen carbonate (221.9 g) was added followed by water (763.4 ml) and tert-butyl methyl ether (763.4 ml). The mixture was stirred vigorously for 2 hours then filtered to give a product which was washed with ter# butyl methyl ether (500 ml) and then dried under vacuum at 45-50°C for 21 hours to give 5-methoxy-2-{[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methyljsulphinyl}-1 H-benzimidazole (293.4 g, 77% yield, purity by HPLC 98.3%).
Example 7 A mixture of 5-methoxy-2-mercapto-1 H-benzimidazole (4.3 g), methanol (8.4 ml) and water (16.7 ml) was stin-ed while sodium hydroxide solution (4.7 ml, 46-48% wlw) was added over 5 minutes. The mixture was stirred at 45-50°C and a solution of 2-chloromethyl-4-methoxy-3,5-dimethylpyridine hydrochloride (5.3 g) in water (25 ml) was added over 35 minutes at 45-50°C. The mixture was stirred at 45-50°C for 1.75 hours and then sodium perborate tetrahydrate (4.5 g) was added.
The mixture was stirred at 45-50°C for 20 hours. Further sodium perborate tetrahydrate (0.35 g) was added and the mixture was stirred at 45-50°C
for a further 3 hours. A final batch of sodium perborate tetrahydrate (0.35 g) was added and the mixture stirred for a further 2 hours at 45-50°C. The mixture was cooled to 35°C and 5 sodium hydrogen carbonate (4.9 g) was added followed by water (16.7 ml) and diisopropyl ether (16.2 ml). The mixture was stirred rapidly at 20-25°C
for 1.5 hours.
The mixture was filtered to give a product which was washed with water and dried under vacuum at 45-50°C to give 5-methoxy-2-{[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methyl]sulphinyl}-1 H benzimidazole (6.5 g, 78.9% yield, purity by HPLC
95.5%).
Example 8 A mixture of 5-methoxy-2-mercapto-1 H-benzimidazole (4.3 g), methanol (8.4 ml) and water (16.7 ml) was stirred while sodium hydroxide solution (4.7 ml, 46-48% w/w) was added over 5 minutes. The mixture was stirred at 45-50°C and a solution of 2-chloromethyl-4-methoxy-3,5-dimethylpyridine hydrochloride (5.3 g) in water (25 ml) was added over 35 minutes at 45-50°C. The mixture was stirred at 45-50°C for 1.75 hours and then sodium perborate tetrahydrate (4.5 g) was added.
The mixture was stirred at 45-50°C for 20 hours. Further sodium perborate tetrahydrate (0.35 g) was added and the mixture was stirred at 45-50°C
for a further 3 hours. The mixture was cooled to 35°C and sodium , hydrogen carbonate (4.9 g) was added followed by water (16.7 ml) and hexane (16.7 ml). The mixture was stirred rapidly at 20-25°C for 1.5 hours. The mixture was filtered to give a product which was washed with water and dried under vacuum at 45-50°C to give 5-methoxy-2-~[(4-methoxy-3,5-dimethyl-pyridin-2-yi)methyl]sulphinyl}-1H
benzimidazole (6.6 g, 80.4% yield, purity by HPLC 94.45%).
Claims (17)
1. A process for the preparation a compound of formula I
in which R1, R2, R3 and R4 represent a) (R1=CH3; R2=OCH3; R3=CH3; R4=OCH3) or b) (R1=CH3; R2=OCH2CF3; R3=H; R4=H) or c) (R1=OCH3; R2=OCH3; R3=H and R4=OCHF2) respectively and pharmaceutically acceptable salts thereof comprising reacting a compound of formula II
in which R1, R2, R3 and R4 represent a) (R1=CH3; R2=OCH3; R3=CH3; R4=OCH3) or b) (R1=CH3; R2=OCH2CF3; R3=H; R4=H) or c) (R1=OCH3; R2=OCH3; R3=H and R4=OCHF2) respectively with a perborate salt in a liquid diluent at a pH in the range of 7.5 to 14 at a temperature in the range of 0°C to the boiling point of the liquid diluent employed.
in which R1, R2, R3 and R4 represent a) (R1=CH3; R2=OCH3; R3=CH3; R4=OCH3) or b) (R1=CH3; R2=OCH2CF3; R3=H; R4=H) or c) (R1=OCH3; R2=OCH3; R3=H and R4=OCHF2) respectively and pharmaceutically acceptable salts thereof comprising reacting a compound of formula II
in which R1, R2, R3 and R4 represent a) (R1=CH3; R2=OCH3; R3=CH3; R4=OCH3) or b) (R1=CH3; R2=OCH2CF3; R3=H; R4=H) or c) (R1=OCH3; R2=OCH3; R3=H and R4=OCHF2) respectively with a perborate salt in a liquid diluent at a pH in the range of 7.5 to 14 at a temperature in the range of 0°C to the boiling point of the liquid diluent employed.
2. A process as claimed in claim 1 wherein the perborate salt is sodium perborate.
3. A process as claimed in either claim 1 or claim 2 in which the amount of perborate salt employed in the process is in the range of 0.8 to 3 moles per mole of the compound of formula II employed in the process.
4. A process according to any previous claim in which the liquid diluent is selected from water, a C1-4 alcohol, toluene, tetrahydrofuran, acetone, a C2-6 diol, a C3-6 triol, ethyl acetate or mixtures thereof.
5. A process according to any previous claim in which the liquid diluent is a water/alcohol mixture.
6. A process according to any previous claim in which the process is carried out at a pH in the range of 8.5 to 12.
7. A process according to any previous claim in which a salt of the desired product is obtained.
8. A process according to any previous claim in which the compound of formula I is isolated as the free heterocycle.
9. A process according to any previous claim in which the process is carried out at a temperature in the range of 0 to 150°C.
10. A process according to claim 1 in which a compound of formula Ila is reacted with sodium perborate in a mixture of water and methanol at a pH in the range of 8.5 to 10 at a temperature in the range of 15 -115°C to give a compound of formula Ia (omeprazole).
11. A process according to any previous claim wherein a purification solvent is added at the end of the oxidation reaction.
12. A process according to claim 11 wherein the purification solvent is a hydrocarbon or an ether.
13. A process according to claim 12 wherein the purification solvent is selected from tert-butyl methyl ether or diisopropyl ether.
14. A process according to any previous claim in which the compound of formula II used is prepared by reacting a compound of formula III
or a salt thereof in which R4 is as previously defined with a compound of formula IV
or a salt thereof in which R1, R2, and R3 are as previously defined, optionally in the presence of a base, in a second liquid diluent at a pH in the range of 7.5 to 14 at a temperature in the range of 0°C to the boiling point of the liquid diluent employed and is then reacted with a perborate salt without isolation.
or a salt thereof in which R4 is as previously defined with a compound of formula IV
or a salt thereof in which R1, R2, and R3 are as previously defined, optionally in the presence of a base, in a second liquid diluent at a pH in the range of 7.5 to 14 at a temperature in the range of 0°C to the boiling point of the liquid diluent employed and is then reacted with a perborate salt without isolation.
15. A process according to claim 14 wherein the second liquid diluent is selected from water, a C1-4 alcohol, toluene, tetrahydrofuran, acetone, a C2-6 diol, a C3-6 triol, ethyl acetate or mixtures thereof.
16. A process according to claim 15 wherein the second liquid diluent is the same as the first.
17. A process according to any one of claims 14-16 wherein sodium hydroxide is used as the base.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9805558.5 | 1998-03-17 | ||
GBGB9805558.5A GB9805558D0 (en) | 1998-03-17 | 1998-03-17 | Chemical process` |
PCT/EP1999/001574 WO1999047514A1 (en) | 1998-03-17 | 1999-03-11 | Chemical process for the production of sulphinyl derivatives by oxidation of the corresponding co-derivatives with perborates |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2323422A1 true CA2323422A1 (en) | 1999-09-23 |
Family
ID=10828629
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002323422A Abandoned CA2323422A1 (en) | 1998-03-17 | 1999-03-11 | Chemical process for the production of sulphinyl derivatives by oxidation of the corresponding co-derivatives with perborates |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1071678A1 (en) |
JP (1) | JP2002506862A (en) |
KR (1) | KR20010041948A (en) |
CN (1) | CN1293670A (en) |
AU (1) | AU3410699A (en) |
BR (1) | BR9908835A (en) |
CA (1) | CA2323422A1 (en) |
GB (1) | GB9805558D0 (en) |
HU (1) | HUP0101230A3 (en) |
IL (1) | IL138001A0 (en) |
NO (1) | NO20004580L (en) |
SK (1) | SK13452000A3 (en) |
TR (1) | TR200002670T2 (en) |
TW (1) | TW473476B (en) |
WO (1) | WO1999047514A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19951960C2 (en) * | 1999-10-28 | 2002-06-27 | Gruenenthal Gmbh | Process for the preparation of benzimidazole derivatives suitable as ulcer therapeutics |
KR20040029966A (en) * | 2001-02-02 | 2004-04-08 | 테바 파마슈티컬 인더스트리즈 리미티드 | Processes for the production of substituted 2-(2-pyridylmethyl)sulfinyl-1h-benzimidazoles |
KR100547824B1 (en) | 2001-12-29 | 2006-02-01 | 삼성전자주식회사 | Method for transmitting emergency call in mobile communication terminal having bluetooth |
US6909004B2 (en) | 2002-08-21 | 2005-06-21 | Teva Pharmaceutical Industries Ltd. | Method for the purification of lansoprazole |
JP2005527638A (en) | 2002-11-18 | 2005-09-15 | テバ ファーマシューティカル インダストリーズ リミティド | Stable lansoprazole containing more than 500 ppm to about 3000 ppm water and more than 200 ppm to about 5000 ppm alcohol |
EP1575941B1 (en) | 2002-12-06 | 2012-04-11 | Nycomed GmbH | Process for preparing (S)-pantoprazole |
JP2006514108A (en) | 2002-12-19 | 2006-04-27 | テバ ファーマシューティカル インダストリーズ リミティド | Solid state of pantoprazole sodium, process for preparing them, and process for preparing known pantoprazole sodium hydrate |
CA2515130A1 (en) | 2003-02-05 | 2004-08-26 | Teva Pharmaceutical Industries Ltd. | Method of stabilizing lansoprazole |
CA2528993A1 (en) | 2003-06-10 | 2004-12-23 | Teva Pharmaceutical Industries Ltd. | Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole |
SI1802584T1 (en) | 2004-10-11 | 2010-01-29 | Ranbaxy Lab Ltd | Processes for the preparation of substituted sulfoxides |
CN102603621B (en) * | 2012-02-07 | 2013-09-04 | 成都苑东药业有限公司 | Novel chiral sulfoxide compound and method for preparing esomeprazole by using novel chiral sulfoxide compound |
CN107365300B (en) * | 2017-07-26 | 2019-08-02 | 桂林华信制药有限公司 | A method of effectively removing impurity in Lansoprazole crude product |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE416649B (en) * | 1974-05-16 | 1981-01-26 | Haessle Ab | PROCEDURE FOR THE PREPARATION OF SUBSTANCES WHICH PREVENT Gastric acid secretion |
SE8500996D0 (en) * | 1985-03-01 | 1985-03-01 | Haessle Ab | METHOD OF TREATMENT |
JPH0352887A (en) * | 1989-07-20 | 1991-03-07 | Yoshitomi Pharmaceut Ind Ltd | Pyridine compound |
WO1991019712A1 (en) * | 1990-06-20 | 1991-12-26 | Aktiebolaget Astra | Dialkoxy-pyridinyl-benzimidazole derivatives, process for their preparation and their pharmaceutical use |
ES2026761A6 (en) * | 1990-10-31 | 1992-05-01 | Genesis Para La Investigacion | A process for the preparation of omeprazol. |
DE69826900T2 (en) * | 1997-07-11 | 2005-11-24 | Eisai Co., Ltd. | Process for the preparation of pyridine derivatives |
-
1998
- 1998-03-17 GB GBGB9805558.5A patent/GB9805558D0/en not_active Ceased
-
1999
- 1999-03-11 JP JP2000536710A patent/JP2002506862A/en active Pending
- 1999-03-11 BR BR9908835-5A patent/BR9908835A/en not_active Application Discontinuation
- 1999-03-11 TR TR2000/02670T patent/TR200002670T2/en unknown
- 1999-03-11 AU AU34106/99A patent/AU3410699A/en not_active Abandoned
- 1999-03-11 HU HU0101230A patent/HUP0101230A3/en unknown
- 1999-03-11 CN CN99804078A patent/CN1293670A/en active Pending
- 1999-03-11 IL IL13800199A patent/IL138001A0/en unknown
- 1999-03-11 SK SK1345-2000A patent/SK13452000A3/en unknown
- 1999-03-11 KR KR1020007010261A patent/KR20010041948A/en not_active Application Discontinuation
- 1999-03-11 EP EP99915569A patent/EP1071678A1/en not_active Withdrawn
- 1999-03-11 WO PCT/EP1999/001574 patent/WO1999047514A1/en not_active Application Discontinuation
- 1999-03-11 CA CA002323422A patent/CA2323422A1/en not_active Abandoned
- 1999-03-17 TW TW088104130A patent/TW473476B/en active
-
2000
- 2000-09-14 NO NO20004580A patent/NO20004580L/en unknown
Also Published As
Publication number | Publication date |
---|---|
HUP0101230A2 (en) | 2001-10-28 |
TW473476B (en) | 2002-01-21 |
HUP0101230A3 (en) | 2002-10-28 |
KR20010041948A (en) | 2001-05-25 |
TR200002670T2 (en) | 2000-11-21 |
JP2002506862A (en) | 2002-03-05 |
BR9908835A (en) | 2000-11-21 |
AU3410699A (en) | 1999-10-11 |
NO20004580D0 (en) | 2000-09-14 |
GB9805558D0 (en) | 1998-05-13 |
CN1293670A (en) | 2001-05-02 |
IL138001A0 (en) | 2001-10-31 |
WO1999047514A1 (en) | 1999-09-23 |
NO20004580L (en) | 2000-09-14 |
SK13452000A3 (en) | 2001-04-09 |
EP1071678A1 (en) | 2001-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2450433C (en) | Improved process for preparing benzimidazole-type compounds | |
JP2993122B2 (en) | Synthetic method of omeprazole | |
EP2186807B1 (en) | Process for the preparation of esomeprazole magnesium dihydrate | |
CA2289409C (en) | Sulfoxide compounds and acetone complexes, and a process for producing the same | |
KR101180530B1 (en) | Pharmaceutical process and compounds prepared thereby | |
AU2002321204A1 (en) | Improved process for preparing benzimidazole-type compounds | |
CA2323422A1 (en) | Chemical process for the production of sulphinyl derivatives by oxidation of the corresponding co-derivatives with perborates | |
EP0868423A1 (en) | Method for the synthesis of a benzimidazole compound | |
EP2030973A1 (en) | Process for preparing 2-sulfinyl-1H-benzimidazoles | |
US7557218B2 (en) | Hydrates of optionally substituted 2-(2-pyridinyl) methylthio-1H-benzimidazoles and process for the production thereof | |
WO2010134099A1 (en) | One pot process for preparing omeprazole and related compounds | |
MXPA00008482A (en) | Chemical process for the production of sulphinyl derivatives by oxidation of the corresponding co-derivatives with perborates | |
WO2002074766A1 (en) | Method of preparing lansoprazole and its intermediate | |
US7557217B2 (en) | Process for production of benzimidazole derivative salt precipitate | |
WO2007066202A1 (en) | Process for the preparation of 2-(2-pyridylmethyl)-sulfinyl-1h-benzimidazoles | |
CZ20003173A3 (en) | Process for preparing sulfinyl derivatives by oxidation of corresponding Co-derivatives by peroxometaborates | |
WO2007129328A2 (en) | Process for preparing 2-[pyridinyl]sulfinyl-substituted benzimidazoles | |
SK5892002A3 (en) | Method for producing therapeutic agents for ulcers | |
KR100783020B1 (en) | Method of preparing 2-methylchloride pyridine derivatives and benzimidazole derivatives thereof | |
MX2011005981A (en) | A new process for preparing 4- [4-methyl-5- (cl- 10alkylthio/c5-10aryl-cl-6alkylthio) -4h-1, 2, 4-triazol-3- yl] pyridines. | |
KR20020026016A (en) | Preparation of sulfinyl compounds using a metal catalyst |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |